A randomised controlled trial of Dexamethasone for Emergency and Life-Threatening Admissions due to COVID-19 in Virtual Care: the DELTA study

Royal Prince Alfred Hospital0 个研究点目标入组 650 人开始时间: 2021年9月8日最近更新: 2021年12月21日

适应症

试验速览

暂无简介。

•Adult patients (age greater than or equal to 18 years)
•-Currently under the care of RPAV in the community or Special Health Accommodation (SHA)
•-Confirmed COVID-19 on Polymerase Chain Reaction (PCR) testing within the last 14 days
•-Exhibiting mild/moderate COVID-19 symptoms (fever, respiratory tract symptoms, chest pain, lethargy, dizziness, myalgia, anosmia, dyspnea, headache, gastrointestinal symptoms), with no requirement for oxygen or hospitalization
•-Requiring nursing or medical assessment by RPA Virtual Hospital clinicians within 72 hours for new or escalating symptoms of mild to moderate COVID-19

•-Currently taking oral or inhaled corticosteroids
•-Major medical or psychiatric comorbidities precluding the use of corticosteroids (e.g. poorly controlled diabetes mellitus, chronic heart disease, chronic renal disease, chronic liver failure, schizophrenia or thought disorder, bipolar disorder)
•-Immunosuppression or treatment for malignancy
•-Hypersensitivity to corticosteroids, thiamine, wheat, lactose, povidone, maize starch or magnesium stearate
•-History of alcohol dependence or at risk alcohol intake
•-At risk for thiamine deficiency (e.g. eating disorders, chronic malabsorption)
•-Requires urgent transfer to the emergency department at the time of assessment
•-Patient declines or is unable to provide consent
•-Lactating or pregnant women
•-No access to a personal or loaned electronic device,
•-Unable to read or write English

发起方